Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05583552 |
|
Recruitment Status :
Recruiting
First Posted : October 17, 2022
Last Update Posted : February 6, 2024
|
Sponsor:
GCP-Service International West GmbH
Collaborators:
Geron Corporation
Universitätsklinikum Leipzig
Saint-Louis Hospital, Paris, France
QIMR Berghofer Medical Research Institute
Australasian Leukaemia and Lymphoma Group
Groupe Francophone des Myelodysplasies
German Myelodysplastic Syndrome Study Group
Information provided by (Responsible Party):
GCP-Service International West GmbH
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | February 2025 |
| Estimated Study Completion Date : | June 2026 |